Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice.
Johan K E SpetzBritta LangenNils RudqvistToshima Z ParrisKhalil HelouOla NilssonEva Forssell-AronssonPublished in: BMC cancer (2017)
A comparative analysis of the different treatment groups showed that combination therapy using sonidegib and 177Lu-octreotate could be beneficial to patients with neuroendocrine tumors. Gene expression analysis revealed a functional interaction between sonidegib and 177Lu-octreotate, i.e. several cancer-related signaling pathways were modulated that were not affected by either monotherapy. Protein expression analysis indicated a possible PI3K/AKT/mTOR-dependent activation of the Hh pathway, independent of SMO.
Keyphrases
- neuroendocrine tumors
- combination therapy
- genome wide identification
- endothelial cells
- signaling pathway
- transcription factor
- single cell
- copy number
- stem cells
- clinical trial
- randomized controlled trial
- type diabetes
- high fat diet induced
- epithelial mesenchymal transition
- gene expression
- protein protein
- insulin resistance
- pluripotent stem cells
- induced apoptosis
- small molecule
- amino acid
- cell therapy
- study protocol
- wild type